Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Antonarakis, Emmanuel S.
Madison, Russell
Snider, Jeremy
Snow, Tamara
Sokol, Ethan
Chung, Jon
McCusker, Margaret Elizabeth
Singal, Gaurav
Alexander, Brian Michael
Castellanos, Emily
Venstrom, Jeffrey
Schrock, Alexa Betzig
Ross, Jeffrey S.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] Flatiron Hlth, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5527
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).
    Su, Christopher T.
    Nizialek, Emily
    Berchuck, Jacob E.
    Vlachostergios, Panagiotis J.
    Ashkar, Ryan
    Sokolova, Alexandra
    Barata, Pedro C.
    Aggarwal, Rahul Raj
    McClure, Heather
    Nafissi, Nellie
    Bryce, Alan Haruo
    Sartor, A. Oliver
    Cheng, Heather H.
    Adra, Nabil
    Sternberg, Cora N.
    Taplin, Mary-Ellen
    Cieslik, Marcin
    Antonarakis, Emmanuel S.
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).
    Barata, Pedro C.
    Montgomery, Rachel
    Last, Matthew
    Gillespie-Akar, Liane
    Nazari, Jonathan
    Arondekar, Bhakti
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease
    Schmidt, Andrew Lachlan
    Anton, Angelyn
    Wong, Shirley S.
    Azad, Arun
    Kwan, Edmond Michael
    Spain, Lavinia Anne
    Torres, Javier
    Muthusamy, Arunbalaji
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey C.
    Joshua, Anthony M.
    Pook, David William
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
    Raju, Rachel
    Sahu, Arvind
    Klevansky, Myron
    Torres, Javier
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [6] Survival and fracture risk with radium-223 therapy in metastatic castrate-resistant prostate cancer (mCRPC): A real-world analysis
    Zhang, Hanbo
    Graham, Jeffrey
    Czaykowski, Piotr
    Gingerich, Joel Roger
    Bybel, Bohdan
    Dawe, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 50 - 50
  • [7] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI
    Watson, Alexander S.
    Gagnon, Richard
    Batuyong, Eugene
    Alimohamed, Nimira
    Lee-Ying, Richard
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 496.e1 - 496.e9
  • [9] Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer
    Parikh, S.
    Murray, L.
    Kenning, L.
    Bottomley, D.
    Din, O.
    Dixit, S.
    Ferguson, C.
    Handforth, C.
    Joseph, L.
    Mokhtar, D.
    White, L.
    Wright, G.
    Henry, A. M.
    CLINICAL ONCOLOGY, 2018, 30 (09) : 548 - 555
  • [10] Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations.
    Marshall, Catherine Handy
    McNatty, Andrea
    Eisenberger, Mario A.
    Bryce, Alan Haruo
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345